Literature DB >> 10681275

Changes in definitions of clinical staging for carcinoma of the cervix and ovary: International Federation of Gynecology and Obstetrics.

.   

Abstract

Entities:  

Mesh：

Year:  1987        PMID： 10681275

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN： 0002-9378            Impact factor:   8.661


× No keyword cloud information.
  23 in total

1.  Prognosis and prognostic factors of the micropapillary pattern in patients treated for stage II and III serous borderline tumors of the ovary.

Authors:  Catherine Uzan; Aminata Kane; Annie Rey; Sebastien Gouy; Sophie Camatte; Patricia Pautier; Catherine Lhommé; Christine Haie-Meder; Pierre Duvillard; Philippe Morice
Journal:  Oncologist       Date:  2011-01-27

2.  Endometrial and Ovarian Cancer with MR Imaging Importance of Serum HE4 and CA 125 Levels in the Extent of Disease at Evaluation.

Authors:  Emsal Pınar Topdağı Yılmaz; Yakup Kumtepe
Journal:  Eurasian J Med       Date:  2016-10

3.  Serous ovarian carcinoma patients with high alpha-folate receptor had reducing survival and cytotoxic chemo-response.

Authors:  Yu-Li Chen; Ming-Cheng Chang; Chia-Yen Huang; Ying-Cheng Chiang; Han-Wei Lin; Chi-An Chen; Chang-Yao Hsieh; Wen-Fang Cheng
Journal:  Mol Oncol       Date:  2011-12-20       Impact factor: 6.603

4.  Prognostic effect of epidermal growth factor receptor gene mutations and the aberrant phosphorylation of Akt and ERK in ovarian cancer.

Authors:  Yoshimichi Tanaka; Yoshito Terai; Akiko Tanabe; Hiroshi Sasaki; Tatsuharu Sekijima; Satoe Fujiwara; Yoshiki Yamashita; Masanori Kanemura; Masatsugu Ueda; Michio Sugita; Wilbur A Franklin; Masahide Ohmichi
Journal:  Cancer Biol Ther       Date:  2011-01-01       Impact factor: 4.742

5.  Predictive value of ATP7b, BRCA1, BRCA2, PARP1, UIMC1 (RAP80), HOXA9, DAXX, TXN (TRX1), THBS1 (TSP1) and PRR13 (TXR1) genes in patients with epithelial ovarian cancer who received platinum-taxane first-line therapy.

Authors:  S Pontikakis; C Papadaki; M Tzardi; M Trypaki; M Sfakianaki; F Koinis; E Lagoudaki; L Giannikaki; A Kalykaki; E Kontopodis; Z Saridaki; N Malamos; V Georgoulias; J Souglakos
Journal:  Pharmacogenomics J       Date:  2016-10-25       Impact factor: 3.550

6.  Bcl-2 and p53 protein expression, apoptosis, and p53 mutation in human epithelial ovarian cancers.

Authors:  W Y Chan; K K Cheung; J O Schorge; L W Huang; W R Welch; D A Bell; R S Berkowitz; S C Mok
Journal:  Am J Pathol       Date:  2000-02       Impact factor: 4.307

7.  Proteolytic cleavage of the CD44 adhesion molecule in multiple human tumors.

Authors:  Isamu Okamoto; Hiromasa Tsuiki; Lawrence C Kenyon; Andrew K Godwin; David R Emlet; Marina Holgado-Madruga; Irene S Lanham; Christopher J Joynes; Kim T Vo; Abhijit Guha; Mitsuhiro Matsumoto; Yukitaka Ushio; Hideyuki Saya; Albert J Wong
Journal:  Am J Pathol       Date:  2002-02       Impact factor: 4.307

Review 8.  Management, prognosis and reproductive outcomes of borderline ovarian tumor relapse during pregnancy: from diagnosis to potential treatment options.

Authors:  Francesco Cosentino; Luigi Carlo Turco; Stefano Cianci; Francesco Fanfani; Anna Fagotti; Salvatore Gueli Alletti; Giuseppe Vizzielli; Salvatore Giovanni Vitale; Antonio Simone Laganà; Francesco Padula; Claudio Coco; Salvatore Pisconti; Giovanni Scambia
Journal:  J Prenat Med       Date:  2016 Jan-Jun

9.  DNA-cytophotometry and immunocytochemistry in ovarian tumours of borderline malignancy and related peritoneal lesions.

Authors:  B C Padberg; H E Stegner; S von Sengbusch; H Arps; S Schröder
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1992

10.  Depletion of regulatory T lymphocytes reverses the imbalance between pro- and anti-tumor immunities via enhancing antigen-specific T cell immune responses.

Authors:  Yu-Li Chen; Ming-Cheng Chang; Chi-An Chen; Han-Wei Lin; Wen-Fang Cheng; Chung-Liang Chien
Journal:  PLoS One       Date:  2012-10-17       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.